Brachytherapy in Cervical Cancer

Opening Scientific Plenary

2019 Presidential Award Winning Abstract

Dendritic cell-based immunotherapy

News Coverage

• ASCO Post 3/19/19 SGO 2019: HPV Vaccine Uptake in the Deep South
• ECancer TV 3/21/19 Study shows HPV-related cancer incidence rates, not traditional disparities, affect Alabama’s HPV vaccine uptake
• Oncology Times 3/17/19 Study Shows HPV-Related Cancer Incidence Rates, Not Traditional Disparities, Affect Alabama’s HPV Vaccine Uptake
• Precision Vaccinations 3/21/19 Alabama’s HPV-Related Cancer Rate Unusually Varies By County
• ASCO Post 3/19/19 SGO 2019: Dendritic Cell–Based Immunotherapy in Combination With Chemotherapy in Recurrent Ovarian Cancer
• CancerConnect 3/21/19 Novel Vaccine May Represent New Treatment Option for Ovarian Cancer
• CancerNetwork 3/21/19 SGO 2019: TWiST Backs Benefits of PARP Inhibitor in Ovarian Cancer
• Cure Today 3/17/19 Zejula Maintenance Therapy Extends Survival with Toxicities in Recurrent Ovarian Cancer
• ECancer TV 3/21/19 Immunotherapy improves prognosis for women with recurrent ovarian cancer in clinical trial
• HemOnc Today (Healio) 3/20/19 Dendritic cell-based immunotherapy regimen extends OS in recurrent ovarian cancer
• MedPage Today 3/17/19 PARP Inhibitor Benefit Gets aTWiST in Recurrent Ovarian Cancer
• OncLive 3/19/19 Adding Dendritic Cell-Based Immunotherapy to Chemo Improves OS in Relapsed Ovarian Cancer
• Precision Vaccinations 3/21/19 Immunotherapy Improves Prognosis for Recurrent Ovarian Cancer Patients
• Targeted Oncology 3/22/19 Expert Highlights OS Improvement With Dendritic Cell-Based Immunotherapy and Chemo in Relapsed Ovarian Cancer
• ASCO Post 3/19/19 SGO 2019: Treatment With Maintenance Niraparib in Recurrent Ovarian Cancer Extends Time Without Symptoms or Toxicity
• Cancer Therapy Advisor 3/16/19 The Relationship Between Niraparib Dose Reduction and Efficacy in Ovarian Cancer
• Cure Today 3/18/19 Individualized Dosing Regimen Reduces Side Effects in Ovarian Cancer Maintenance Therapy
• ECancer TV 3/21/19 Ovarian cancer drug niraparib maintains remission and extends time without symptoms
• HemOnc Today (Healio) 3/16/19 Niraparib extends time without symptoms for women with recurrent ovarian cancer
• OncLive 3/16/19 Maintenance Niraparib Extends PFS Without Symptoms Toxicities in Recurrent Ovarian Cancer
• Physicians Briefing 3/22/19 Niraparib Extends Time Without Symptoms in Ovarian Cancer
• PracticeUpdate 3/16/19 SGO 2019: In Recurrent Ovarian Cancer, Niraparib Tolerability Improves by Starting With 200 and 300 mg Based on Body Weight and Platelet Count
• PracticeUpdate 3/16/19 SGO 2019: Niraparib Maintains Remission and Extends Symptom-Free Interval in Recurrent Ovarian Cancer
• Targeted Oncology 3/17/19 PFS Increased With Niraparib Without Symptoms or Toxicity in Ovarian Cancer
• ASCO Post 3/19/19 SGO 2019: Brachytherapy Boost Added to EBRT and Chemotherapy in Advanced Cervical Cancer
• Cancer Therapy Advisor 3/16/19 Racial Disparities in the Use of Brachytherapy to Treat Cervical Cancer
• ECancer TV 3/21/19 Internal radiation therapy is critical to improving survival among women undergoing multimodal treatment for locally advanced cervical cancer
• HemOnc Today (Healio) 3/17/19 Brachytherapy improves survival in advanced cervical cancer, but racial disparities remain
• MedPage Today 3/17/19 Standard Brachytherapy Underused in Cervical Cancer
• PracticeUpdate 3/16/19 SGO 2019: Internal Radiotherapy is Critical to Improve Survival Among Women Undergoing Multimodal Treatment for Locally Advanced Cervical Cancer
• Physician’s Briefing 3/25/19 Brachytherapy Boost Ups Survival in Locally Advanced Cervical Cancer
• Specialty Medical Dialogues 3/29/19 Brachytherapy improves Survival in Locally Advanced Cervical Cancer